Matrixx net sales down
This article was originally published in The Tan Sheet
Executive Summary
Sales of Zicam cough/cold products increased about 15% in Matrixx Initiatives' second quarter, the firm reports Oct. 24. Marketing spending for the 2007/2008 cold season will increase 15%, the company projects. However, net sales in the July-September period for the Phoenix-based OTC healthcare firm fell 16% to $28.6 mil. and net income declined 10.4% to $6.4 mil. In a same-day earnings call, Matrixx executives said the firm's performance is in line with expectations due to large retail customers' caution in off-season purchases of cough/cold products...
You may also be interested in...
Matrixx reports lowest cold season since 1999
Phoenix-based Matrixx Initiatives announced Jan. 16 the incidence of illness for the 2007/2008 season, which runs October to March, has hit the lowest level since its Zicam cough/cold brand was introduced in 1999, which affected reorders the firm received in the third quarter ended Dec. 31, 2007 ("The Tan Sheet" Oct. 29, 2007, In Brief). Matrixx anticipates sales for the quarter to fall below $36.2 million and a net loss "on par" with $463,000, as recorded in the quarter ended Dec. 31, 2006. The firm will update the previously issued guidance for fiscal 2008, but says its most recent tracking data shows an increase in illness and if it continues, it anticipates its fiscal 2008 net sales to be at 5 percent or above the $97.6 million recorded at the end of fiscal 2007. The firm expects to report net income between $9 million and $10 million, or $.90 and $1.00 per share...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.